Nature Communications (Jul 2023)

Genome-wide screening in pluripotent cells identifies Mtf1 as a suppressor of mutant huntingtin toxicity

  • Giorgia Maria Ferlazzo,
  • Anna Maria Gambetta,
  • Sonia Amato,
  • Noemi Cannizzaro,
  • Silvia Angiolillo,
  • Mattia Arboit,
  • Linda Diamante,
  • Elena Carbognin,
  • Patrizia Romani,
  • Federico La Torre,
  • Elena Galimberti,
  • Florian Pflug,
  • Mirko Luoni,
  • Serena Giannelli,
  • Giuseppe Pepe,
  • Luca Capocci,
  • Alba Di Pardo,
  • Paola Vanzani,
  • Lucio Zennaro,
  • Vania Broccoli,
  • Martin Leeb,
  • Enrico Moro,
  • Vittorio Maglione,
  • Graziano Martello

DOI
https://doi.org/10.1038/s41467-023-39552-9
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 24

Abstract

Read online

Abstract Huntington’s disease (HD) is a neurodegenerative disorder caused by CAG-repeat expansions in the huntingtin (HTT) gene. The resulting mutant HTT (mHTT) protein induces toxicity and cell death via multiple mechanisms and no effective therapy is available. Here, we employ a genome-wide screening in pluripotent mouse embryonic stem cells (ESCs) to identify suppressors of mHTT toxicity. Among the identified suppressors, linked to HD-associated processes, we focus on Metal response element binding transcription factor 1 (Mtf1). Forced expression of Mtf1 counteracts cell death and oxidative stress caused by mHTT in mouse ESCs and in human neuronal precursor cells. In zebrafish, Mtf1 reduces malformations and apoptosis induced by mHTT. In R6/2 mice, Mtf1 ablates motor defects and reduces mHTT aggregates and oxidative stress. Our screening strategy enables a quick in vitro identification of promising suppressor genes and their validation in vivo, and it can be applied to other monogenic diseases.